https://www.zacks.com/stock/news/2220251/regeneron-regn-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2220251
Feb 02, 2024 - Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zc:-54377411717849244
0
https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619
Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
zc:6649813996292415733
0
https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-r-d-assets-to-regeneron-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218877
Jan 31, 2024 - 2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.
zc:6104452854925000797
0
https://www.zacks.com/stock/news/2217967/deciphera-pharmaceuticals-inc-dcph-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2217967
Jan 30, 2024 - Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:-7836930265063462866
0
https://www.zacks.com/stock/news/2215118/here-s-why-investors-may-bet-on-biomarin-bmrn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2215118
Jan 24, 2024 - Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.
zc:4058698359472848859
0
https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367
Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
zc:5586419536017940380
0
https://www.zacks.com/stock/news/2212927/mesoblast-meso-up-on-rare-pediatric-disease-tag-for-heart-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212927
Jan 19, 2024 - Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.
zc:6994723974281765028
0
https://www.zacks.com/stock/news/2212386/maia-soars-20-on-interim-results-from-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2212386
Jan 18, 2024 - MAIA Biotechnology (MAIA) reports updated results from a mid-stage study. Patients treated with its lead drug achieved disease control rates that were well-sustained compared with previous scans.
zc:-5634115568131083711
0
https://www.zacks.com/stock/news/2212290/is-it-a-good-idea-to-invest-in-intellia-ntla-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2212290
Jan 18, 2024 - Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.
zc:6966983953777213566
0
https://www.zacks.com/stock/news/2212231/here-s-why-you-should-invest-in-avadel-avdl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2212231
Jan 18, 2024 - Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.
zc:1371741271837818172
0